Pancreatic Cancer Diagnostics Market to Grow with a CAGR of 7.05% through 2030
Increasing
incidence of pancreatic cancer, and rising demand for minimally invasive
diagnostic procedures are expected to drive the growth of Global Pancreatic
Cancer Diagnostics Market in the forecast period, 2026-2030.
According
to TechSci Research report, “Pancreatic Cancer Diagnostics
Market –Global Industry Size, Share, Trends, Opportunity, and Forecast,
2030F,” the Global Pancreatic Cancer Diagnostics
Market stood at USD 2.87 billion in 2024 and is anticipated to grow with a
CAGR of 7.05% in the forecast period through 2030. This can be ascribed to the
increasing incidence of pancreatic cancer, rising demand for minimally invasive
diagnostic procedures, and growing investment in research and development.
The
COVID-19 pandemic has had a significant impact on the global healthcare
industry, including the market for pancreatic cancer diagnostics. While the
pandemic has led to increased demand for COVID-19 testing, it has also
disrupted routine healthcare services, including cancer screening and
diagnostic procedures. The market for pancreatic cancer diagnostics has been
particularly affected by the pandemic. As hospitals and healthcare facilities
focus on treating COVID-19 patients, many elective procedures, including cancer
screening and diagnostic tests, have been postponed or canceled. This has led
to a decline in demand for pancreatic cancer diagnostic tests, as patients are
unable or unwilling to undergo these procedures during the pandemic.
There are
some challenges that are hampering the growth of global pancreatic cancer
diagnostics market in the forecast period. These challenges include the lack of
early symptoms, limited diagnostic tools, lack of reliable biomarkers,
difficulty in distinguishing between pancreatic cancer and other pancreatic
conditions, and the limited effectiveness of current treatment options.
Browse over XX market data Figures spread through XX
Pages and an in-depth TOC on "Global Pancreatic Cancer Diagnostics Market.”
Global
Pancreatic Cancer Diagnostics Market can be segmented by test type, by
cancer type, by end user, by regional distribution and company.
Based on Test Type, Blood Tests are gaining momentum and are
expected to see rapid growth in the coming years. This is driven by the growing
demand for early cancer detection and ongoing technological advancements in
biomarker discovery. Pancreatic cancer often leads to elevated levels of
certain tumor markers in the blood, such as CA 19-9 and carcinoembryonic
antigen, making blood tests a useful diagnostic tool. Additionally, with
increasing attention on genetic testing and personalized medicine, advanced blood-based
diagnostic tools like multi-cancer early detection (MCED) tests are seeing
wider adoption. These innovations are paving the way for less invasive, more
accessible methods of detecting pancreatic cancer at earlier stages.
Based on Region, The Asia Pacific region is witnessing
the fastest growth in the pancreatic cancer diagnostics market due to a
combination of demographic, lifestyle, and healthcare system changes. One of
the primary factors fueling this growth is the increasing population,
particularly the aging demographic, which is more susceptible to cancer-related
diseases, including pancreatic cancer. As the region becomes more urbanized and
lifestyles become more sedentary, risk factors such as obesity, diabetes, and smoking
— all known contributors to pancreatic cancer — are on the rise. These shifts
in public health dynamics are prompting a greater need for early and accurate
diagnostic tools.
In response, many countries in the Asia Pacific region have
been investing more in healthcare infrastructure, particularly in diagnostics
and screening facilities. Governments and health agencies are becoming more
aware of the need for early cancer detection and have initiated programs that
emphasize timely screening and diagnosis. Public awareness campaigns are also
contributing to increased demand for diagnostic services as more people seek
evaluations for symptoms that could indicate underlying conditions like
pancreatic cancer.
Major
companies operating in Global Pancreatic Cancer Diagnostics
Market are:
- Siemens
Healthineers AG
- Myriad
Genetics, Inc.
- Pfizer,
Inc
- Novartis
AG
- AstraZeneca
plc
- Immunovia
AB
- Laboratory
Corporation of America Holdings
- Abbott
Laboratories
- Agilent
Technologies, Inc.
- Thermo
Fisher Scientific Inc.
Download Free Sample Report
Customers
can also request for 10% free customization on this report.
“The global
pancreatic cancer diagnostics market is poised for significant growth in the
coming years, driven by increasing incidence of the disease and a growing need
for improved diagnostic tools and techniques. While there are challenges the
market will face, such as the difficulty of diagnosing the disease in its early
stages and the high cost of diagnostic tests, innovative companies and
researchers are working hard to develop new and better diagnostic tools that
can improve outcomes for patients with pancreatic cancer.” said Mr. Karan
Chechi, Research Director of TechSci Research, a research based global
management consulting firm.
“Pancreatic Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type {Diagnostic Imaging Tests (CT scan, MRI, Ultrasound, Others), Biopsy, Blood Tests, Liver Function Tests, Others}, By Cancer Type (Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Colloid Carcinoma, Others), By End User (Hospitals & Clinics, Diagnostic Centers, Others), By Region and Competition, 2020-2030F”, has evaluated the future growth potential
of Global Pancreatic Cancer Diagnostics Market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Pancreatic Cancer Diagnostics
Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com